Molecular and nutritional markers in head and neck cancer.

IF 2.8 4区医学 Q2 ONCOLOGY

Current Opinion in Oncology Pub Date : 2024-05-01 Epub Date: 2024-02-29 DOI:10.1097/CCO.0000000000001034

Gerard Milano, Jocelyn Gal, René-Jean Bensadoun

{"title":"Molecular and nutritional markers in head and neck cancer.","authors":"Gerard Milano, Jocelyn Gal, René-Jean Bensadoun","doi":"10.1097/CCO.0000000000001034","DOIUrl":null,"url":null,"abstract":"Purpose of review: There is still a need of biomarkers in the induction and neoadjuvant settings for squamous cell carcinoma of the head and neck (SCCHN). The objective of this concise review article is to give an overview on both predictive and prognostic biomarkers potentially useful for the management of SCCHN.Recent findings: Human papilloma virus (HPV) positivity translated by the presence of the protein indicator p16 is synonymous of favorable prognosis SCCHN. However, there is some disparity for disease evolution among p16 positive SCCHN. A lack of correlation between immunohistochemistry (IHC) and precise quantification of active epidermal growth factor receptors (EGFRs) may explain the absence of link between EGFR expression performed by IHC and response to EGFR targeting therapies reported in SCCHN. Circulating tumor cells (CTCs) have the property to share the main somatic mutations and genetic rearrangements with the primary tumors. A particular potential interest lies on the possibility to predict patient outcome based on a single-CTC analysis.Summary: This short review indicates that key biological marker reflecting disease outcome is not yet emerging for a clinical use in SCCHN. Hopes can be put into the so-called liquid biopsies incorporating circulating tumor cells and circulating tumor DNA.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"123-127"},"PeriodicalIF":2.8000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCO.0000000000001034","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/29 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: There is still a need of biomarkers in the induction and neoadjuvant settings for squamous cell carcinoma of the head and neck (SCCHN). The objective of this concise review article is to give an overview on both predictive and prognostic biomarkers potentially useful for the management of SCCHN.

Recent findings: Human papilloma virus (HPV) positivity translated by the presence of the protein indicator p16 is synonymous of favorable prognosis SCCHN. However, there is some disparity for disease evolution among p16 positive SCCHN. A lack of correlation between immunohistochemistry (IHC) and precise quantification of active epidermal growth factor receptors (EGFRs) may explain the absence of link between EGFR expression performed by IHC and response to EGFR targeting therapies reported in SCCHN. Circulating tumor cells (CTCs) have the property to share the main somatic mutations and genetic rearrangements with the primary tumors. A particular potential interest lies on the possibility to predict patient outcome based on a single-CTC analysis.

Summary: This short review indicates that key biological marker reflecting disease outcome is not yet emerging for a clinical use in SCCHN. Hopes can be put into the so-called liquid biopsies incorporating circulating tumor cells and circulating tumor DNA.

查看原文本刊更多论文

头颈癌的分子和营养标记。

综述目的：头颈部鳞状细胞癌（SCCHN）的诱导和新辅助治疗仍需要生物标志物。这篇简明综述文章旨在概述可能有助于头颈部鳞状细胞癌治疗的预测性和预后性生物标志物：最新发现：人乳头状瘤病毒（HPV）阳性与蛋白指标 p16 的存在是预后良好的 SCCHN 的同义词。然而，p16 阳性的 SCCHN 在疾病演变方面存在一些差异。免疫组化（IHC）与活性表皮生长因子受体（EGFR）的精确定量之间缺乏相关性，这可能是IHC检测的EGFR表达与SCCHN报告的EGFR靶向疗法反应之间缺乏联系的原因。循环肿瘤细胞（CTCs）具有与原发肿瘤共享主要体细胞突变和基因重排的特性。根据单个 CTC 分析预测患者预后的可能性具有特别的潜在意义。摘要：这篇简短的综述表明，反映疾病预后的关键生物标志物尚未在 SCCHN 临床应用中出现。所谓的液体活检包括循环肿瘤细胞和循环肿瘤 DNA。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Oncology 医学-肿瘤学

CiteScore

6.10

自引率

2.90%

发文量

130

审稿时长

4-8 weeks

期刊介绍： With its easy-to-digest reviews on important advances in world literature, Current Opinion in Oncology offers expert evaluation on a wide range of topics from sixteen key disciplines including sarcomas, cancer biology, melanoma and endocrine tumors. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by annotated references detailing the merits of the most important papers.